UK drug regulator approves Alzheimer's drug but government likely won't pay for it
Britainโs drug regulator has authorized the Alzheimerโs drug Leqembi, saying that itโs the first medicine to show some impact in slowing progression of the neurodegenerative disease.
It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
The first drug shown to slow Alzheimerโs hit the U.S. market over a year ago, but sales have lagged and diagnosis and treatment remain complicated.
FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer's drug
Federal regulators are putting off a decision on Eli Lillyโs potential Alzheimerโs treatment with an unusual request to have an advisory committee examine the drug.
First FDA approved drug to slow Alzheimerโs
More than six million Americans are living with Alzheimerโs disease โ it slowly steals your memories and takes away your mind. There is no cure, yet, but now, a newly FDA-approved drug is helping to slow its progression before itโs too late.
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety risk
New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.
Alzheimerโs drug Leqembi has full FDA approval now and that means Medicare will pay for it
U.S. officials have granted full approval to a closely watched Alzheimerโs drug for patients with early stages of the disease.
FDA to make a decision on whether to approve first Alzheimerโs drug
The FDA is set to decide whether it will fully approve the first Alzheimerโs drug to show it could slow the diseaseโs progression in certain patients. But the decision could also have other implications, including who would get access to it.